Bayer has decided to discontinue a phase 3 trial of its oral Factor XIa inhibitor asundexian in patients with atrial fibrillation ... have already suffered an acute non-cardioembolic ischaemic ...

The study was published online in JAMA Neurology on March 31, 2025.

The trial – sponsored by the University of Liverpool – will collect data from acute ischaemic stroke ... research portfolio into stroke and atrial fibrillation research, and would help inform ...

The system, which has received CE Mark approval in Europe, adds to an increasingly crowded field of PFA technologies.

Atrial Fibrillation (Afib ... an incidental diagnosis is given during a hospital visit or in the event of an acute stroke. The abnormal rhythm that Afib causes, stops the heart from pumping ...

With surveillance, conversion to acute valve syndrome happened frequently and was linked to worse clinical outcomes.

(JAMA) A randomized trial found that for patients with acute heart failure and pleural effusion ... Pulsed field ablation or cryoballoon ablation for paroxysmal atrial fibrillation? A Swiss trial says ...

Whereas obesity is a common confounder when interpreting natriuretic peptide values, and the presence of atrial fibrillation has an important influence on pretest probability, other confounders are ...

Congress, Johnson & Johnson MedTech presented pivotal 12-month safety and effectiveness data from the SmartfIRE study—offering new insights into the future of atrial fibrillation (AFib) treatment. The ...